drugset / Trial / NCT05294172
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1
Timeline
- Start
- 2022-06-07
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KL-A167 | Unknown | 1200 mg | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |